{"url_path":"/sec/hrgn/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1563665/0001437749-26-016761-index.html","accession_number":"0001437749-26-016761","cik":"0001563665","ticker":"HRGN","issuer_name":"Harvard Apparatus Regenerative Technology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1563665/0001437749-26-016761-index.html","primary_entity_key":"0001563665","primary_entity_name":"Harvard Apparatus Regenerative Technology, Inc."},"word_count":733,"has_tables":true,"body_markdown":"hrgn20260331_10q.htm\n\n0001563665\nHarvard Apparatus Regenerative Technology, Inc.\nfalse\n--12-31\nQ1\n2026\n\n0.01\n0.01\n60,000,000\n60,000,000\n17,580,744\n17,580,744\n17,580,744\n17,580,744\n2\n0\n0\n0\n898,622\n5.33\n4\n10\n3\n0\n0\n2\n2\nfalse\nfalse\nfalse\nfalse\nCertain general and administrative costs (including executive compensation, corporate legal fees, audit fees, investor relations, and insurance) are shared across both segments. For internal reporting purposes, such costs are allocated to each segment based on an estimate of the proportion of management time and corporate resources utilized by each segment. Costs directly attributable to a segment are charged directly to that segment. For the three months ended March 31, 2026 and 2025, the Regenerative Biotech segment bore substantially all general and administrative expense, as the Consumer Health Products segment incurred minimal shared corporate overhead.\n“Other segment items” for the Regenerative Biotech segment consists primarily of net interest income earned on money market balances and other miscellaneous income, partially offset by interest expense on insurance premium financing. For the Consumer Health Products segment, other segment items consist of foreign currency transaction effects and other minor income items. The other segment items line represents the arithmetic difference between segment revenues, less the significant expense categories disclosed above, and the reported segment net loss, in accordance with ASC 280-10-50-26B.\n\n00015636652026-01-012026-03-31\nxbrli:shares\n00015636652026-05-04\nthunderdome:item\niso4217:USD\n00015636652026-03-31\n00015636652025-12-31\niso4217:USDxbrli:shares\n00015636652025-01-012025-03-31\n0001563665us-gaap:CommonStockMember2025-12-31\n0001563665us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001563665us-gaap:RetainedEarningsMember2025-12-31\n0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-31\n0001563665us-gaap:CommonStockMember2026-01-012026-03-31\n0001563665us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001563665us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-31\n0001563665us-gaap:CommonStockMember2026-03-31\n0001563665us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001563665us-gaap:RetainedEarningsMember2026-03-31\n0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-31\n0001563665us-gaap:CommonStockMember2024-12-31\n0001563665us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001563665us-gaap:RetainedEarningsMember2024-12-31\n0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31\n00015636652024-12-31\n0001563665us-gaap:CommonStockMember2025-01-012025-03-31\n0001563665us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001563665us-gaap:RetainedEarningsMember2025-01-012025-03-31\n0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31\n0001563665us-gaap:CommonStockMember2025-03-31\n0001563665us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001563665us-gaap:RetainedEarningsMember2025-03-31\n0001563665us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-31\n00015636652025-03-31\n0001563665hrgn:InsurancePremiumFinancingPayableMember2026-01-012026-03-31\n0001563665hrgn:InsurancePremiumFinancingPayableMember2025-01-012025-03-31\nxbrli:pure\n00015636652024-07-31\n0001563665hrgn:ClinicalActivityTrialsMember2026-01-012026-03-31\n0001563665hrgn:ClinicalActivityTrialsMember2026-03-31\n0001563665hrgn:OtherDepositsMember2026-03-31\nutr:Y\n0001563665us-gaap:ComputerEquipmentMember2026-03-31\n0001563665hrgn:FurnitureMachineryAndEquipmentMembersrt:MinimumMember2026-03-31\n0001563665hrgn:FurnitureMachineryAndEquipmentMembersrt:MaximumMember2026-03-31\n0001563665us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhrgn:HealthRegenMember2026-01-012026-03-31\n0001563665us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhrgn:HealthRegenMember2025-01-012025-03-31\n0001563665us-gaap:PrivatePlacementMember2025-12-302025-12-30\n0001563665us-gaap:PrivatePlacementMember2025-12-30\n0001563665us-gaap:PrivatePlacementMember2025-07-112025-07-11\n0001563665us-gaap:PrivatePlacementMember2025-07-11\n0001563665hrgn:EquityIncentivePlanMember2026-01-012026-03-31\n0001563665hrgn:EquityIncentivePlanMember2026-03-31\n00015636652025-01-012025-12-31\n0001563665hrgn:PerformanceBasedStockOptionsMemberhrgn:EquityIncentivePlanMember2026-03-31\n0001563665hrgn:NonPerformanceBasedOptionsMemberhrgn:EquityIncentivePlanMember2026-03-31\n0001563665hrgn:NonPerformanceBasedOptionsMemberhrgn:EquityIncentivePlanMember2026-01-012026-03-31\n0001563665hrgn:ResearchAndDevelopmentMemberhrgn:EquityIncentivePlanMember2026-01-012026-03-31\n0001563665hrgn:ResearchAndDevelopmentMemberhrgn:EquityIncentivePlanMember2025-01-012025-03-31\n0001563665hrgn:GeneralAndAdministrativeMemberhrgn:EquityIncentivePlanMember2026-01-012026-03-31\n0001563665hrgn:GeneralAndAdministrativeMemberhrgn:EquityIncentivePlanMember2025-01-012025-03-31\n0001563665hrgn:EquityIncentivePlanMember2025-01-012025-03-31\nutr:sqft\n0001563665hrgn:HQOperatingLeaseAgreementMember2024-08-12\n0001563665hrgn:ServicesAgreementWithBeijingQuarkmedTechnologyCoLtdMember2025-07-01\n0001563665hrgn:ServicesAgreementWithBeijingQuarkmedTechnologyCoLtdMember2025-09-30\n0001563665hrgn:ServicesAgreementWithBeijingQuarkmedTechnologyCoLtdMember2026-03-31\n0001563665hrgn:InsurancePremiumFinancingPayableMember2025-11-30\n0001563665hrgn:InsurancePremiumFinancingPayableMember2026-03-31\n0001563665hrgn:HQOperatingLeaseAgreementMember2026-03-31\n0001563665hrgn:ResearchAndDevelopmentMember2026-01-012026-03-31\n0001563665hrgn:ResearchAndDevelopmentMember2025-01-012025-03-31\n0001563665hrgn:GeneralAndAdministrativeMember2026-01-012026-03-31\n0001563665hrgn:GeneralAndAdministrativeMember2025-01-012025-03-31\n0001563665us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\n0001563665us-gaap:EmployeeStockOptionMember2025-01-012025-03-31\n0001563665us-gaap:WarrantMember2026-01-012026-03-31\n0001563665us-gaap:WarrantMember2025-01-012025-03-31\n0001563665hrgn:RegenerativeBiotechMember2026-01-012026-03-31\n0001563665hrgn:ConsumerHealthProductsMember2026-01-012026-03-31\n0001563665hrgn:RegenerativeBiotechMember2025-01-012025-03-31\n0001563665hrgn:ConsumerHealthProductsMember2025-01-012025-03-31\n0001563665hrgn:RegenerativeBiotechMember2026-03-31\n0001563665hrgn:RegenerativeBiotechMember2025-12-31\n0001563665hrgn:ConsumerHealthProductsMember2026-03-31\n0001563665hrgn:ConsumerHealthProductsMember2025-12-31\n0001563665hrgn:TheBridgeNoteMemberus-gaap:SubsequentEventMember2026-05-08\n\n \n\n \n\n[Table of Contents](#toc)\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n☒ **Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\n**For the quarterly period ended March 31, 2026**\n\n \n\n☐ **Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\n**For the transition period from to**\n\n \n\n**Commission file number 001-35853**\n\n \n\n**Harvard Apparatus Regenerative Technology, Inc.**\n\n**(Exact Name of Registrant as Specified in Its Charter)**\n\n \n\n**Delaware**\n \n**45-5210462**\n\n**(State or Other Jurisdiction of**\n \n**(IRS Employer**\n\n**Incorporation or Organization)**\n \n**Identification No.)**\n\n \n\n**84 October Hill Road, Suite 11, Holliston, MA**\n \n**01746**\n\n**(Address of Principal Executive Offices)**\n \n**(Zip Code)**\n\n \n\n**(774) 233-7300**\n\n**(Registrant**’**s telephone number, including area code)**\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act: None\n\n \n\nTitle of each class\n \nTrading Symbol(s)\n \nName of each exchange on which registered\n\nN/A\n \nN/A\n \nN/A\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐\n\nAccelerated filer ☐\n\n  \n\nNon-accelerated filer ☒\n\nSmaller reporting company ☒\n\n  \n\n \nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No\n\n \n\nAs of May 4, 2026, there were 17,580,744 shares of common stock, par value $0.01 per share, outstanding.\n\n \n\n \n\n \n\n[Table of Contents](#toc)\n\n \n\n \n\n**Harvard Apparatus Regenerative Technology, Inc.**\n\n**Form 10-Q**\n\n**For the Quarter Ended March 31, 2026**\n\n \n\n**INDEX**\n\n \n\n \n \n\n**Page**\n\n[PART I-FINANCIAL INFORMATION](#part1)\n\n[5](#part1)"}